Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

ted antibodies in combination with a wide range of anti-cancer agents, including many commonly prescribed chemotherapeutic drugs. This patent was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

The Phase II trial of bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients has a Simon two-stage design. In the first stage, 15 patients with advanced breast cancer were enrolled and treated with the combination regimen. Nine of the 14 (64%) evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria, exceeding the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

"Completion of patient enrollment in our second Phase II breast cancer study marks another milestone for the bavituximab cancer program, with two of our three ongoing Phase II trials now having completed enrollment," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe the rapid enrollment experienced in all three of these trials is representative of the enthusiasm of our clinical investigators as well as the need for improved cancer therapies. We look forward to reporting further data from these studies in the upcoming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. They may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... for a moment that Silicon Graphics Inc. (better ... days before its Altix 3000 family of servers and superclusters ... SGI rolled out the latest version of its popular ... the Mountain View-based company, whose only manufacturing facility is in ...
... Internet programming? Is tech still an exciting space to work ... with computers was an introductory programming class in 1979 using ... fledgling Internet when I started college in 1985. There have ... programming and the business of information technology as interesting and ...
... giant Eli Lilly & Company recently expressed concern to ... HIPAA privacy rule may impede clinical research trials. , ... and approve thousands of patient authorizations for use and ... Crosley, chief privacy officer of Indianapolis-based Eli Lilly. ...
Cached Biology Technology:SGI, Introduces Powerful High End Visualization Tools 2SGI, Introduces Powerful High End Visualization Tools 3Interview: Billpoint Founder Jason May on eBay, Open Source 2Interview: Billpoint Founder Jason May on eBay, Open Source 3Interview: Billpoint Founder Jason May on eBay, Open Source 4
(Date:7/9/2014)... healthy women differ from bacteria in women with ... from Loyola University Chicago Stritch School of Medicine. ... in the American Society for Microbiology,s online journal ... play a role in female urinary health. , ... poorly understood, condition with symptoms similar to urinary ...
(Date:7/9/2014)... the Spanish National Cancer Research Centre (CNIO) have discovered ... also regulates cell division in stratified epitheliathose that form ... the oesophagus or the vaginain adult organisms. According to ... Nature Communications , this factor could also play ... stratified epithelia of the oesophagus and skin. , The ...
(Date:7/9/2014)... Researchers studying critically ill children with traumatic injuries ... patients are likely to develop a hospital-acquired infection. ... Hospital and published online in June in the ... larger efforts that could lead to the clinical ... to prevent or reverse immune system damage following ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... (January 24, 2014) A new study published in ... egg production has increased over the past 50 years, the ... footprint. Researchers conducted a lifecycle analysis of U.S. egg production ... the complete lifecycle from crops to hens to the farm ...
... novel high-throughput screening process, scientists have for the first time ... a toxic eye protein that can lead to early onset ... can damage the eye,s optic nerve and cause vision loss ... for optic nerve damage. Researchers have implicated a ...
... the human gut and their impact on human health and ... research today. To address the most recent advances in this ... the world will come together at the Gut Microbiota for ... 9, 2014. The meeting is hosted by the Gut Microbiota ...
Cached Biology News:Landmark egg production study reveals reduction in environmental impact over past 50 years 2Landmark egg production study reveals reduction in environmental impact over past 50 years 3Researchers discover potential drug targets for early onset glaucoma 2Researchers discover potential drug targets for early onset glaucoma 3Attend the Gut Microbiota for Health World Summit 2014 2
...
... T4 DNA Ligase catalyzes the formation ... ATP between double-stranded DNAs with 3' hydroxyl ... DNA Ligase buffer optimizes ligation which can ... nucleic acids are not substrates for this ...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Biology Products: